These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 25405974)
21. An integrated approach for prioritizing pharmaceuticals found in the environment for risk assessment, monitoring and advanced research. Caldwell DJ; Mastrocco F; Margiotta-Casaluci L; Brooks BW Chemosphere; 2014 Nov; 115():4-12. PubMed ID: 24636702 [TBL] [Abstract][Full Text] [Related]
22. Medicating the environment: assessing risks of pharmaceuticals to wildlife and ecosystems. Arnold KE; Brown AR; Ankley GT; Sumpter JP Philos Trans R Soc Lond B Biol Sci; 2014 Nov; 369(1656):. PubMed ID: 25405959 [TBL] [Abstract][Full Text] [Related]
23. Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach. Kar S; Roy K; Leszczynski J Methods Mol Biol; 2018; 1800():395-443. PubMed ID: 29934904 [TBL] [Abstract][Full Text] [Related]
24. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process. Laenge R; Steger-Hartmann T; Schweinfurth H Regul Toxicol Pharmacol; 2006 Aug; 45(3):223-8. PubMed ID: 16716476 [TBL] [Abstract][Full Text] [Related]
25. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383 [TBL] [Abstract][Full Text] [Related]
26. Prioritization and analysis of pharmaceuticals for human use contaminating the aquatic ecosystem in Italy. Riva F; Zuccato E; Castiglioni S J Pharm Biomed Anal; 2015 Mar; 106():71-8. PubMed ID: 25459268 [TBL] [Abstract][Full Text] [Related]
27. The accessibility of data on environmental risk assessment of pharmaceuticals - are environmental risk assessments information on emissions with respect to international and European environmental information law? Oelkers K Regul Toxicol Pharmacol; 2020 Mar; 111():104571. PubMed ID: 31893528 [TBL] [Abstract][Full Text] [Related]
28. Reporting and evaluation criteria as means towards a transparent use of ecotoxicity data for environmental risk assessment of pharmaceuticals. Ågerstrand M; Küster A; Bachmann J; Breitholtz M; Ebert I; Rechenberg B; Rudén C Environ Pollut; 2011 Oct; 159(10):2487-92. PubMed ID: 21763042 [TBL] [Abstract][Full Text] [Related]
29. Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case. Ortiz de García S; Pinto GP; García-Encina PA; Irusta Mata RI J Environ Manage; 2013 Nov; 129():384-97. PubMed ID: 23995140 [TBL] [Abstract][Full Text] [Related]
30. A ranking of European veterinary medicines based on environmental risks. Kools SA; Boxall A; Moltmann JF; Bryning G; Koschorreck J; Knacker T Integr Environ Assess Manag; 2008 Oct; 4(4):399-408. PubMed ID: 18563959 [TBL] [Abstract][Full Text] [Related]
31. Are exposure predictions, used for the prioritization of pharmaceuticals in the environment, fit for purpose? Burns EE; Thomas-Oates J; Kolpin DW; Furlong ET; Boxall ABA Environ Toxicol Chem; 2017 Oct; 36(10):2823-2832. PubMed ID: 28477358 [TBL] [Abstract][Full Text] [Related]
32. Fighting trafficking of falsified and substandard medicinal products in Russia. Fayzrakhmanov NF Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702 [TBL] [Abstract][Full Text] [Related]
33. Human and environmental risk assessment of pharmaceuticals: differences, similarities, lessons from toxicology. Dorne JL; Skinner L; Frampton GK; Spurgeon DJ; Ragas AM Anal Bioanal Chem; 2007 Feb; 387(4):1259-68. PubMed ID: 17186225 [TBL] [Abstract][Full Text] [Related]
34. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Borg JJ; Aislaitner G; Pirozynski M; Mifsud S Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243 [TBL] [Abstract][Full Text] [Related]
35. Occurrence and fate of micropollutants in the Vidy Bay of Lake Geneva, Switzerland. Part I: priority list for environmental risk assessment of pharmaceuticals. Perazzolo C; Morasch B; Kohn T; Magnet A; Thonney D; Chèvre N Environ Toxicol Chem; 2010 Aug; 29(8):1649-57. PubMed ID: 20821616 [TBL] [Abstract][Full Text] [Related]
36. Identification and evaluation of computer models for predicting environmental concentrations of pharmaceuticals and veterinary products in the Nordic environment. Wajsman D; Rudén C J Expo Sci Environ Epidemiol; 2006 Jan; 16(1):85-97. PubMed ID: 16030525 [TBL] [Abstract][Full Text] [Related]
37. Regulatory demands on data quality for the environmental risk assessment of pharmaceuticals. Küster A; Bachmann J; Brandt U; Ebert I; Hickmann S; Klein-Goedicke J; Maack G; Schmitz S; Thumm E; Rechenberg B Regul Toxicol Pharmacol; 2009 Dec; 55(3):276-80. PubMed ID: 19607869 [TBL] [Abstract][Full Text] [Related]
38. Pharmaceuticals in the environment: lessons learned for reducing uncertainties in environmental risk assessment. Brooks BW; Berninger JP; Kristofco LA; Ramirez AJ; Stanley JK; Valenti TW Prog Mol Biol Transl Sci; 2012; 112():231-58. PubMed ID: 22974742 [TBL] [Abstract][Full Text] [Related]
39. European medicines and feed additives regulation are not in compliance with environmental legislation and policy. Montforts MH; de Knecht JA Toxicol Lett; 2002 May; 131(1-2):125-36. PubMed ID: 11988365 [TBL] [Abstract][Full Text] [Related]
40. Occurrence and ecotoxicological assessment of pharmaceuticals: Is there a risk for the Mediterranean aquatic environment? Desbiolles F; Malleret L; Tiliacos C; Wong-Wah-Chung P; Laffont-Schwob I Sci Total Environ; 2018 Oct; 639():1334-1348. PubMed ID: 29929299 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]